Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT06704321 Sponsor: Valbiotis Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT06704321
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 75 years old (inclusive)
  • People whose liver scan (FibroScan®) shows a high level of fat in the liver (CAP Score ≥288 dB/m) but low levels of liver stiffness, suggesting little to no scarring (fibrosis score F0 to F1, below 8 kPa)
  • People with a body mass index (BMI) between 25 and 40, and a waist circumference that meets specific thresholds set out in international liver disease guidelines (confirm with trial site for exact measurements)
  • People whose weight has stayed roughly the same (within 5% up or down) over the past three months

Who may not be able to join:

  • People who are unable to have an MRI scan, FibroScan®, or a DEXA bone/body composition scan for any reason
  • People living with a metabolic condition that could significantly affect blood sugar or fat levels in the blood, or that might otherwise interfere with the study results (confirm with trial site)
  • People with high blood pressure that is not well controlled (a top number of 160 or more, or a bottom number of 100 or more)
  • People who have a history of heart disease related to narrowing or hardening of the arteries (such as a heart attack or stroke caused by plaque build-up)
  • People currently taking medications that could affect the study results (confirm with trial site for specific medications)
  • People who drink above the study's alcohol limits — more than 10 drinks per week for women or 15 per week for men (or more than 3 drinks on any single day for women, or 4 for men) — or people who are unwilling to keep their drinking habits the same throughout the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: André Marette, PhD, Laval University

Phone: +33 (0)6 75 32 66 59

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Valbiotis
Registry
ClinicalTrials.gov
Start date
31 January 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Evolution of liver fat content

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov